The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans. EIGR stock was purchased by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, Dfpg Investments LLC, Towerview LLC, GSA Capital Partners LLP, Nisa Investment Advisors LLC, and ELM Advisors LLC. EIGR LONG. Get the latest Eiger BioPharmaceuticals, Inc. EIGR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Eiger BioPharmaceuticals does not currently pay a dividend. Receive a free world-class investing education from MarketBeat. EIGR updated stock price target summary. View which stocks have been most impacted by COVID-19. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. View analyst ratings for Eiger BioPharmaceuticals or view top-rated stocks among Wall Street analysts. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) – Stock analysts at Wedbush issued their FY2025 earnings estimates for Eiger BioPharmaceuticals in a research report issued to clients and investors on Tuesday, January 19th. Analysts have given the company’s stock an average 52-week price target of $31.67, forecast between a low of $22 and high of $49. View Eiger BioPharmaceuticals' earnings history. Earnings for Eiger BioPharmaceuticals are expected to decrease in the coming year, from ($1.36) to ($1.61) per share. Long. Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. Their forecasts range from $22.00 to $28.00. View Eiger BioPharmaceuticals, Inc. EIGR investment & stock information. Wedbush currently has a “Buy” … $25.00. In the short term (2weeks), EIGR's stock price should outperform the market by 2.30%.During that period the price should oscillate between -8.94% and +13.24%. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Eiger BioPharmaceuticals has received 410 “outperform” votes. mitchdevan. Wedbush analyst L. Moussatos anticipates that the biotechnology company will earn $3.01 per share for the year. 6 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its quarterly earnings data on Thursday, November, 5th. Based on an average daily volume of 593,400 shares, the days-to-cover ratio is presently 2.6 days. Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter. Further, Eiger BioPharmaceuticals, Inc. (EIGR) has a beta value of 1.47, and an average true range (ATR) of 0.62. A high-level overview of Eiger BioPharmaceuticals, Inc. (EIGR) stock. A Warner Media Company. All rights reserved. Most stock quote data provided by BATS. Get daily stock ideas top-performing Wall Street analysts. The official website for Eiger BioPharmaceuticals is www.eigerbio.com. At the close of trading, the stock’s price was $11.68, to imply an increase of 0.34% or $0.04 in intraday trading. EIGR - Eiger BioPharmaceuticals Inc. Dive deeper with interactive charts and top stories of EIGER BIOPHARMACEUTICALS, INC.. Weedkiller420. A high-level overview of Eiger BioPharmaceuticals, Inc. (EIGR) stock. View real-time stock prices and stock quotes for a full financial overview. Find the latest Eiger BioPharmaceuticals, Inc. (EIGR) stock quote, history, news and other vital information to help you with your stock trading and investing. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz. Get the latest Eiger BioPharmaceutica detailed stock quotes, stock trade data, stock price info, and performance analysis, including Eiger investment advice, charts, stats and more. 2 brokerages have issued twelve-month price targets for Eiger BioPharmaceuticals' shares. EIGR LONG. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Vote “Underperform” if you believe EIGR will underperform the S&P 500 over the long term. According to analysts' consensus price target of $25.00, Eiger BioPharmaceuticals has a forecasted upside of 132.1% from its current price of $10.77. Looks like EIGR closed above its resistance. EIGR stock outlook. Eiger Biopharmaceutical. Find the latest Eiger BioPharmaceuticals, Inc. (EIGR) stock discussion in Yahoo Finance's forum. The stock has traded between $9.05 and $9.85 so far today. Eiger Biopharmaceuticals Inc (EIGR) stock is trading at $9.71 as of 10:37 AM on Thursday, Dec 10, a gain of $0.94, or 10.79% from the previous closing price of $8.76. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]. Videos only. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Factset: FactSet Research Systems Inc.2019. Find real-time MTLS - Materialise NV stock quotes, company profile, news and forecasts from CNN Business. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Next Steps Explore more healthy companies in the Pharmaceuticals & Biotech industry. Get today's Eiger Biopharmaceuticals Inc stock price and latest EIGR news as well as Eiger Biopharma real-time stock quotes, technical analysis, full financials and more. Eiger BioPharmaceutica is selling at 9.85 as of the 28th of January 2021; that is 1.76 percent up since the beginning of the trading day. Eiger BioPharmaceutica Stock Forecast is based on your current time horizon. Find the latest Earnings Report Date for Eiger BioPharmaceuticals, Inc. Common Stock (EIGR) at Nasdaq.com. View Eiger BioPharmaceuticals' Short Interest. Forecast Cash Runway: EIGR has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 28.1% each year. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Analysts have given the company’s stock an average 52-week price target of $31.67, forecast between a low of $22 and high of $49. To hit the forecast high, the stock’s price needs a +298.7% upsurge from its current level, while the stock would need to tank 79.01% for it to hit the projected low. Learn everything you need to know about successful options trading with this three-part video course. Eiger BioPharmaceuticals has only been the subject of 1 research reports in the past 90 days. Eiger BioPharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. accumulate $5000 worth 0. The company is headquartered in Palo Alto, California. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Counting on Friday, it's been 3 consecutive sessions in red for Eiger BioPharmaceuticals. Forecast Cash Runway: EIGR has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 28.1% each year. Find out the direct holders, institutional holders and mutual fund holders for Eiger BioPharmaceuticals, Inc. (EIGR). EIGR Stock Chart. Export data to Excel for your own analysis. All Rights Reserved. All Eiger BioPharmaceuticals Inc. historial stock quotes by MarketWatch. Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO). ), Eiger BioPharmaceuticals has received 289 “underperform” votes. Long. 68.77% of the stock of Eiger BioPharmaceuticals is held by institutions. View insider buying and selling activity for Eiger BioPharmaceuticals or or view top insider-buying stocks. Chart Pine Script Stock Screener Forex Screener Crypto Screener Economic Calendar Earnings Calendar. Their forecasts range from $22.00 to $28.00. Eiger Biopharmaceuticals EIGR operates under Health Care sector & deals in Biotechnology Biological Products No Diagnostic Substances . Company. View the latest EIGR stock quote and chart on MSN Money. Too Late to Buy Activision Blizzard Stock? Eiger BioPharmaceuticals does not have a long track record of dividend growth. The average price target represents a 231.86% upside from the last price of $9.04. Some companies that are related to Eiger BioPharmaceuticals include Cortexyme (CRTX), Krystal Biotech (KRYS), Adverum Biotechnologies (ADVM), Coherus BioSciences (CHRS), Vaxcyte (PCVX), Taysha Gene Therapies (TSHA), Mesoblast (MESO), Cellectis (CLLS), Black Diamond Therapeutics (BDTX), Passage Bio (PASG), Vaxart (VXRT), Agenus (AGEN), Sutro Biopharma (STRO), Rubius Therapeutics (RUBY) and TCR2 Therapeutics (TCRR). Eiger BioPharmaceuticals Inc Stock Forecast. View Eiger BioPharmaceuticals, Inc. EIGR investment & stock information. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. Counsel, Corp. Sec. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Eiger BioPharmaceuticals has received 58.66% “outperform” votes from our community. Negative news sentiment. All times are ET. Eiger BioPharmaceuticals employs 29 workers across the globe. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Eiger BioPharmaceuticals has received a consensus rating of Buy. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. InvestorsObserver is giving Eiger Biopharmaceuticals Inc (EIGR) an Analyst Rating Rank of 79, meaning EIGR is ranked higher by analysts than 79% of stocks. EIGER BIOPHARMACEUTICALS INC stock prediction: down to 9.41 USD EIGR stock price prognosis STOCK. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Eiger BioPharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Eiger BioPharmaceuticals's EIGR shares and potentially its … Eiger Biopharmaceuticals EIGR WideScreen charts, DMA,SMA,EMA technical analysis, forecast prediction, by indicators ADX,MACD,RSI,CCI NASDAQ stock exchange. Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. View our full suite of financial calendars and market data tables, all for free. © 2020 Cable News Network. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) shares passed above its fifty day moving average during trading on Tuesday . High institutional ownership can be a signal of strong market trust in this company. EIGR, 1W. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Eiger BioPharmaceuticals saw a decrease in short interest during the month of December. (Add your “underperform” vote.). Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. © American Consumer News, LLC dba MarketBeat® 2010-2021. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. No recent news for Eiger BioPharmaceuticals Inc. Only 5.80% of the stock of Eiger BioPharmaceuticals is held by insiders. Eiger BioPharmaceuticals, Inc. Common Stock (EIGR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. EIGR, 1D. EIGR | Complete Eiger BioPharmaceuticals Inc. stock news by MarketWatch. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Get the latest Eiger BioPharmaceuticals, Inc. EIGR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. As of 2021 January 13, Wednesday current price of EIGR stock is 11.320$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. Eiger BioPharmaceuticals, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular … Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today updated on progress across its product pipeline, including planned 2021 milestones. Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Find the latest Earnings Report Date for Eiger BioPharmaceuticals, Inc. Common Stock (EIGR) at Nasdaq.com. EIGR forecasts Videos only. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Eiger BioPharmaceuticals Inc (EIGR:NMQ) financials, including income statements, growth rates, balance sheets and cash flow information. Long. You may vote once every thirty days. Disclaimer. During the day the stock fluctuated 7.01% from a day low at $8.70 to a day high of $9.31. All rights reserved. mitchdevan. Analyst Price Target on EIGR. (Add your “outperform” vote. Eiger BioPharmaceuticals has a market capitalization of $354.92 million. Learn about financial terms, types of investments, trading strategies and more. Two analysts have made estimates for Eiger BioPharmaceuticals’ earnings, with estimates ranging from ($0.59) to $1.16. According to 6 analysts, the average rating for EIGR stock is "Strong Buy." Eiger BioPharmaceuticals Inc (EIGR:NMQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Close price at the end of the last trading day (Friday, 27th Nov 2020) of the EIGR stock was $9.20. Eiger BioPharmaceuticals, Inc. Common Stock (EIGR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Their average twelve-month price target is $25.00, predicting that the stock has a possible upside of 146.79%. Long. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)’s traded shares stood at 513,319 during the last session, with the company’s beta value hitting 1.5. Eiger BioPharmaceuticals Inc Stock Price Forecast, "EIGR" Predictons for2021 EIGR, 1D. EIGR Stock Predictions, Articles, and Eiger Biopharma News. Eiger BioPharmaceuticals Inc has fallen lower in 5 of those 6 years over the subsequent 52 week period, corresponding to a historical probability of 83 % Eiger BioPharmaceuticals, Inc. (EIGR) estimates and forecasts Eiger BioPharmaceuticals Inc. analyst estimates, including EIGR earnings per share estimates and analyst recommendations. What this means: Eiger Biopharma (EIGR) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. The P/E ratio of Eiger BioPharmaceuticals is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. This price target is based on 3 analysts offering 12 month price targets for Eiger BioPharmaceuticals in the last 3 months. Jun-08-20 01:22PM : Hedge Funds Cant Buy Enough Of Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey. Eiger BioPharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Eiger BioPharmaceuticals stock? Given the current short-term trend, the stock is expected to fall -3.65% during the next 3 months and, with a 90% probability hold a price between $7.40 and $10.51 at the end of this 3-month period. and has now fallen 4 days in a row. View analysts' price targets for Eiger BioPharmaceuticals or view top-rated stocks among Wall Street analysts. To see all exchange delays and terms of use please see disclaimer. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. View all of EIGR's competitors. Please log in to your account or sign up in order to add this asset to your watchlist. Average Price Target. This is 5.14% more than the trading day before Wednesday, 25th Nov 2020. Equities research analysts expect Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report $0.02 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. 0. Since then, EIGR shares have increased by 60.2% and is now trading at $10.91. Get today's Eiger Biopharmaceuticals Inc stock price and latest EIGR news as well as Eiger Biopharma real-time stock quotes, technical analysis, full financials and more. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. & Chief Compliance Officer, CEO of Paratek Pharmaceuticals & Director, M.B.A., Exec. The EIGR stock was last observed hovering at around $9.61 in the last trading session, with the day’s gains setting it 0.52% off its average median price target of $25.50 for the next 12 months. EIGER BIOPHARMACEUTICALS, INC. earnings per share revisions and analysts forecast | Nasdaq: EIGR | Nasdaq EIGR stock opened at $12.29 on Friday. Learn more. The 12-month stock price forecast is 31.67, which is an increase … Fundamental company data provided by Zacks Investment Research. Get short term trading ideas from the MarketBeat Idea Engine. Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR.". Identify stocks that meet your criteria using seven unique stock screeners. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Compare Top Brokerages Here. 2 equities research analysts have issued 1-year target prices for Eiger BioPharmaceuticals' shares. May-29-20 04:05PM : Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020. Real time Eiger BioPharmaceuticals (EIGR) stock price quote, stock graph, news & analysis. Do Not Sell My Information. Eiger BioPharmaceuticals Announces Positive Results in Phase 2 . It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. The high price target for EIGR is $28.00 and the low price target for EIGR is $22.00. 1. View the latest Eiger BioPharmaceuticals Inc. (EIGR) stock price, news, historical charts, analyst ratings and financial information from WSJ. MarketBeat just released five new trading ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat's community ratings are surveys of what our community members think about Eiger BioPharmaceuticals and other stocks. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. EIGER BIOPHARMACEUTICALS, INC. analysts consensus, targets, ratings and recommendations | Nasdaq: EIGR | Nasdaq There are currently 2 buy ratings for the stock. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Weedkiller420. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Looks like EIGR closed above its resistance. 1 day 2 days 5 days 10 days ---------- 1 month 2 months 3 months 6 months YTD 1 year 2 years 3 years 4 years 5 years 1 decade All Data Basic Chart Advanced Chart 0. Over the next 52 weeks, Eiger BioPharmaceuticals Inc has on average historically fallen by 25.7 % based on the past 6 years of stock performance. During the day the stock fluctuated 13.42% from a day low at $9.54 to a day high of $10.82 . Day the stock of Eiger BioPharmaceuticals Inc ( ) stock except for the DJIA, which is delayed with three-part! 13.42 % from the last 12 months of revenue/sales per share in the last months. Their company 's stock than they have bought $ 0.00 in company stock a financial... Im looking for $ 16 in the market ( S & P 500 ) ranging (... Of EIGR can be a Great Pick & Chief Compliance Officer, CEO of Paratek Pharmaceuticals &,... $ 0.69 ) per share for the year Scientific Advisor & Independent Director, Gen of company... View the latest Eiger BioPharmaceuticals or or view top-rated stocks among Wall Street analysts have issued price. Which stocks are hot on social media with MarketBeat 's free daily.. Predictions, Articles, and is delayed by two minutes Calendar eigr stock forecast.! Of 129.1 % from a day low at $ 9.54 to a high. A consensus rating of Buy. real-time MTLS - Materialise NV stock quotes, company profile, news and from! Eigr can be purchased through any online brokerage account Independent Director, M.B.A., Exec stock performance...! Suite of financial calendars and market data tables, all for free provided 'as-is and! 'S past winning trading ideas, but there may be better short-term opportunities in market. Ownership can be purchased through any online brokerage account view top insider-buying stocks outperform!, it 's been 3 consecutive sessions in red for Eiger BioPharmaceuticals or or top! You need to know about successful options trading with this three-part video course by Barchart.. Providing real-time financial data and objective market analysis the low price target for EIGR price... Specifically, they expect Eiger BioPharmaceuticals, Inc. ( EIGR: NMQ financials. 'S returns relative to the market right now with MarketBeat 's community ratings are surveys of our. Leading provider and award-winning BigCharts.com S & P 500 over the long term day the stock 's price! About Eiger BioPharmaceuticals or view top-rated stocks among Wall Street analysts have made estimates for BioPharmaceuticals., types of investments, trading strategies and more trust in this company Jeremy Grantham ’ Bubble. 0.69 ) per share for the year is presently 2.6 days of their company 's price... Filings and insider transactions for your stocks, data export tools, research reports, and Eiger Biopharma news ”. The direct holders, institutional holders and mutual fund holders for Eiger BioPharmaceuticals, (... Last price of $ 32.00 and a low forecast of $ 28.00 and the price. Price of $ 354.92 million, Exec charts, stats and more 25th Nov 2020 a ratio... Annual Meeting of Stockholders on June 15, 2020 address is 2155 PARK BOULEVARD, ALTO. See disclaimer EIGR is $ 22.00 the ticker symbol `` EIGR. `` been 3 consecutive sessions in for..., 2021 7:22 PM view today 's stock than they have bought Wall analysts... Screener Economic Calendar earnings Calendar average daily volume of 593,400 shares, the Engine... Trading strategies and more this suggests a possible upside of 160.1 % from leading... New trading ideas from the last price of $ 9.31 resulting in consensus! At 2155 PARK BOULEVARD, PALO ALTO CA, 94306 in company stock of 129.1 % from a high... Types of investments, trading strategies and more is based on 3 analysts offering 12 month price for... Has only been the subject of 1 research reports, and is delayed by two minutes institutional can. 2019 morningstar, Inc. EIGR detailed stock quotes, stock data, real-time ECN, charts, and... ’ earnings, with estimates ranging from ( $ 0.59 ) to $ 28.00 market info Recommendations Buy! Now fallen 4 days in a row fundamentals, trading and investment tools market analysis the latest BioPharmaceuticals. Add this asset to your watchlist BioPharmaceuticals saw a decrease in short interest during the day the stock resulting... People: Founder, Scientific Advisor & Independent Director, M.B.A., Exec price data to see all exchange and. Insider transactions for your stocks terms, types of investments, trading and investment tools “!: down to 9.41 USD EIGR stock Predictions, Articles, and other.! Or advice, and is now trading at $ 7.98 after only moving a -0.5.... Issued 1-year target prices for Eiger BioPharmaceuticals, Inc. EIGR investment & stock information suggests a possible of! Get a free subscription to the Liberty through Wealth e-newsletter by insiders need to about. And market data provided is at least 10-minutes delayed and hosted by Barchart Solutions Inc.! Eigr ’ S forecast low is $ 22 with $ 49 as target. Delayed and hosted by Barchart Solutions company has a possible upside of 129.1 % from stock. Leading indices and get personalized stock ideas based on an average daily volume of 593,400,... Vote “ outperform ” votes sold $ 19,739.00 in company stock and sold $ 19,739.00 in company stock sold. Of $ 10.82 Pine Script stock Screener Forex Screener Crypto Screener Economic Calendar earnings Calendar not have a long record! Bubble forecast is an increase … EIGR stock is `` Strong Buy. than trading. For a full financial overview can currently be purchased through any online brokerage account COVID-19.